Novel biological therapy Availability and affordability in S | 72086
International Research Journals
Reach Us +44 330 818 7254

International Research Journal of Pharmacy and Pharmacology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Novel biological therapy Availability and affordability in Serbia for patients with metastatic colorectal cancer


Kovacevic Aleksandra

Colorectal cancer has been a health burden for many years . Although it's considered to be a disease of the developed world, the incidence rate of CRC has been on the increase in developing countries also (Favoriti et al., 2016; Douaiher et al., 2017). consistent with the planet Health Organization GLOBOCAN database (Bray et al., 2018), is that the third most ordinarily diagnosed cancer and therefore the fourth main explanation for cancer death within the world, accounting for 881,000 deaths in 2018. Colorectal cancer also causes substantial morbidity and mortality in Serbia. consistent with an equivalent database, the amount of latest cases of in 2018 was 6,049 (12.6% of any sort of cancer), while the amount of the deaths caused by was 3,187 (2.9% of all cancerrelated deaths) (The Global Cancer Observatory, 2018). The Serbian health system is facing an additional challenge due to a steep rise in the number of people diagnosed with CRC. From 1997 to 2007, the incidence of CRC increased by 24.6% (Knezevic, 2009). Since this trend will, without doubt, stress the National Health Insurance Fund (NHIF) of Serbia, the objectives of this study were to identify different types of medical services provided to CRC patients and therefore the associated expenditures so as to estimate the entire medical cost at the national level between 2104 and 2017. This information is expected to assist healthcare decision planners and policymakers on how to allocate resources optimally Patients with metastatic colorectal cancer (mCRC) have typically overall survival (OS) of approximately 30 months, if multi disciplinary team approach was applied. The first-line treatment comprises cytotoxic agents, a fluoropyrimidines in various protocols, combined with irinotecan or oxaliplatin. Additional benefit, in the terms of clinical outcome for such patients, is shown by adding the monoclonal antibodies (bevacizumab, as anti-VEGF and cetuximab and panitumumab as anti-EGFR). Secondline treatment comprehends adding the antiangiogenic fusion protein aflibercept or anti-VEGFR2 antibody ramucirumab to the firstline protocols

Share this article